-
1.发明公开
公开(公告)号：EP2155861A1
公开(公告)日：2010-02-24
申请号：EP08742643.3
申请日：2008-04-07
IPC分类号： C12N5/08
CPC分类号： C12N5/0606 , A61K35/545 , C12N5/0609 , C12N2500/02 , C12N2500/14 , C12N2501/115 , C12N2501/235 , C12N2502/1323
摘要： Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.
-
2.发明公开PARTHENOGENIC ACTIVATION OF HUMAN OOCYTES FOR THE PRODUCTION OF HUMAN EMBRYONIC STEM CELLS 有权PARTHENOGENE AKTIVIERUNG MENSCHLICHER OOZYTEN ZUR HERSTELLUNG MENSCHLICHER EMBRYONALER STAMMZELLEN
公开(公告)号：EP1948791A2
公开(公告)日：2008-07-30
申请号：EP06826397.9
申请日：2006-10-19
IPC分类号： C12N5/08
CPC分类号： A61K35/39 , A61K35/15 , A61K35/26 , A61K35/30 , A61K35/32 , A61K35/34 , A61K35/35 , A61K35/36 , C12N5/0606 , C12N5/0609 , C12N9/12 , C12N15/8776 , C12N2500/02 , C12N2500/14 , C12N2501/70 , C12N2501/999 , C12N2502/1323 , C12N2517/10 , C12Y207/11001
摘要： Methods of producing human stem cells are disclosed for parthenogenetically activating human oocytes by manipulation of O2 tension, including manipulation of Ca2+ under high O2 tension and contacting oocytes with serine threonine kinase inhibitors under low O2 tension, isolating inner cell masses (ICMs) from the activated oocytes, and culturing the cells of the isolated ICMs under high O2 tension. Moreover, methods are described for the production of stems cells from activated oocytes in the absence of non-human animal products, including the use of human feeder cells/products for culturing ICM/stem cells. Stem cells produced by the disclosed methods are also described.
摘要翻译： 公开了产生人干细胞的方法，通过操作O 2张力来孤立地激活人卵母细胞，包括在高O 2压力下操作Ca 2+，并在低O 2张力下将卵母细胞与丝氨酸苏氨酸激酶抑制剂接触，将活细胞内细胞团（ICM） 卵母细胞，并在高O 2张力下培养分离的ICM的细胞。 此外，描述了在不存在非人动物产品的情况下从活化的卵母细胞生产茎细胞的方法，包括使用人饲养细胞/产物来培养ICM /干细胞。 还描述了通过公开的方法产生的干细胞。
-
3.发明授权
-
公开(公告)号：EP2155861B1
公开(公告)日：2018-09-05
申请号：EP08742643.3
申请日：2008-04-07
IPC分类号： C12N5/0735
CPC分类号： C12N5/0606 , A61K35/545 , C12N5/0609 , C12N2500/02 , C12N2500/14 , C12N2501/115 , C12N2501/235 , C12N2502/1323
摘要： Methods are disclosed for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis. The protocol as disclosed minimizes the use of animal-derived components, which makes the stem cells more practical for clinical application.
-
-
-
搜索结果
4 条记录 (耗时 0.014 秒)
